Outcomes of early-stage breast cancer patients treated with sequential anthracyclines –taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial
ConclusionLower RDI for the whole anthracycline –taxane protocol is associated with worse patient survival. Every effort should be exercised to avoid unnecessary dose reductions and/or interruptions among early breast cancer patients receiving adjuvant anthracycline–taxane chemotherapy.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Hormones | Study | Taxotere